RESEARCH ARTICLE

Raised CA19–9 and CEA have prognostic relevance in gallbladder carcinoma

Ashish Sachan, Sundeep Singh Saluja, Phani Kumar Nekarakanti, Nimisha, Bhawna Mahajan, Hirdaya H. Nag and Pramod K. Mishra

Abstract

Background: Role of tumor markers in gall bladder carcinoma (GBC) is not well established. We evaluated the prognostic value of carbohydrate antigen 19–9 (CA19–9) and carcinoma embryonic antigen (CEA) in patients with GBC.

Methods: Of the 225 patients of GBC enrolled, 176 patients were included in the study (excluded 49 patients with jaundice). Patients were divided into 3 groups; resectable $n = 92$, unresectable $n = 17$, metastatic $n = 67$. The clinico-pathological characteristics, tumor markers and survival data were analysed. The cutoff values of CA19–9 & CEA for predicting metastases were computed using receiver operating characteristic curve. Kaplan Meir survival and Cox regression analysis were done for factors predicting survival and recurrence.

Results: The median value of Ca19–9 was significantly higher in metastatic group [resectable: 21.3, unresectable: 53.9 and metastatic: 79; $p < 0.001$] but not for CEA [3.5, 7.8 and 5 ng/ml ($p = 0.20$)]. A cutoff value of 72 IU/ml for CA19–9, 5 ng/ml for CEA had a sensitivity and specificity of 52 and 80%, 51 and 72% respectively for detection of metastatic disease. Median, 3-year & 5-year survival were significantly lower in patients with CEA > 4 ($p = 0.041$), Ca19.9 > 37 ($p = 0.019$), T3/T4 ($p = 0.001$), node positive ($p = 0.001$) and presence of perineural invasion ($p = 0.001$). However, on multivariate analysis, only Ca19.9 > 37 predicted recurrence ($p = 0.002$, HR 5.8).

Conclusions: Raised CA19.9 and CEA predict metastatic disease in patients with GBC without jaundice with a high specificity and may help in prognostication of the patient. CA19–9 was better than CEA in prediction of tumor burden and in predicting recurrence.

Keywords: Gall bladder cancer, CEA, CA19–9, Biliary cancer, Radical cholecystectomy
advanced or metastatic) GBC and to identify their prognostic value in patients of GBC without jaundice.

**Methods**

**Patients and methods**

Patients with suspected GBC managed from October 2013 to April 2017 were reviewed from prospectively maintained database.

Informed patient consent was obtained for this research.

**Inclusion criteria**

Patients with GBC without surgical obstructive jaundice (SOJ) were included.

Patients with GBC with SOJ and GBC masquerades who underwent surgical resection for suspected GBC but had benign disease on final histopathology were excluded.

Patients were divided into three groups- resectable, unresectable (because of locally advanced disease) and metastatic disease.

**Definitions**

**Resectable disease**

Patients with GBC without any evidence of unresectability or metastasis underwent curative resection.

**Unresectable disease**

Presence of main portal venous involvement or contralateral hepatic artery involvement either on dual phase contrast CT scan or as observed at operation.

**Metastatic disease**

Presence of biopsy proven inter-aortocaval (IAC) or lymph nodes on left side of coeliac axis, liver metastasis, omental, ovarian or peritoneal deposits were considered as metastatic disease.

**Preoperative work up**

All patients had a detailed clinical evaluation, blood investigations including tumor markers-CEA and CA19–9 and imaging. Chest X-ray, ultrasonography of abdomen with Doppler, dual phase contrast enhanced CT scan (CECT) were routinely done. Upper gastrointestinal endoscopy was done selectively in patients suspected to have gastro-duodenal infiltration. The extent of the disease and Fine needle sampling of Interaortocaval region was done with endoscopic ultrasound. PET CT scan was done in selected patients. AJCC 8th edition was used for staging [11].

**Tumor markers**

Serum CEA and CA19–9 levels were detected by electrochemiluminescence immunoassay (Cobas; Roche Diagnostics, Germany) at the Department of biochemistry, GIPM ER. Normal reference value for CEA and CA19–9 were (0-4 ng/ml) and (0–37 U/ml) respectively.

**Peri-operative strategy**

Patients with resectable disease at outpatient evaluation were admitted for definitive treatment. All patients underwent staging laparoscopy to rule out metastatic disease. Definitive procedure was abandoned if metastases was confirmed on biopsy. Frozen histopathological examination of Interaortocaval lymphnode sample was performed prior to assessment of local resectability. Patients with unresectable disease underwent palliative bypass if required. To obtain R0 status, gallbladder mass with 2 cm liver wedge or segment IVB, V was resected. Patients with T4 disease underwent additional segmental/ sleeve resection of bowel or segmental resection of bile duct to achieve R0 status. Lymph nodes along the hepatoduodenal ligament, pericholedochal, periportal, peripancreatic and right coeliac nodes were cleared as standard lymphadenectomy. Patients with infiltration of the pedicle on the right side underwent extended right hepatectomy. Frozen examination of cystic duct margin was a routine practice. Common bile duct resection was done in patients with obvious infiltration of duct by tumor, presence of malignancy at cystic duct margin on frozen examination and for lymph nodal clearance, if required.

**Follow up**

Patients were assessed clinically; biochemical including liver function tests and ultrasonography of the abdomen at 3 months interval during first year and 6 months interval in later years. A CECT scan of the abdomen was done at 1 year in patients who remained well. It was done earlier if necessitated by clinical or ultrasound findings.

**Chemotherapy**

Patients were treated by multimodality approach with gemcitabine-based chemotherapy in both the adjuvant and palliative setting. Any node positive tumor or T1b disease and above patients were subjected to adjuvant chemotherapy. In Palliative setting maximum possible supportive care was given.

**Parameters recorded**

Clinical and pathological details were collected, including age, gender, serum CEA and CA19–9 levels, Resectable or unresectable or metastatic disease status, resection margin status, AJCC staging of the disease, location of metastasis, survival time, survival status, adjuvant or palliative chemotherapy.
Statistical analysis

Overall survival was measured from the time of resection to death or last followup. All data are presented as median for non-parametric distributions. Statistical analysis was done using SPSS software (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). Categorical variables were compared with the χ2 test or Fisher’s exact test. The cut off value of CA19–9 and CEA were calculated using receiver operating characteristic (ROC) curve in predicting metastatic disease. ROC curve was used to calculate the sensitivity and specificity of the tumor markers. The area under the ROC curve (AUROC) was adopted for the prognostic accuracy. A P value less than 0.05 was considered to indicate statistical significance. Survival analysis was done using Kaplan Meier test and comparison of survival between two groups was done using log rank test. Calculation of hazard ratio, univariate and multivariate analysis was done using Cox regression model.

Results

A total of 225 patients with GBC were evaluated from October 2013 to April 2017. Forty-nine patients who presented with jaundice were excluded. Among the 176 patients included, 92 (52.3%) patients had a resectable disease, 17 (9.6%) were locally advanced & unresectable and 67 (38.1%) had metastatic disease. Among 84 patients with inoperable disease, 45 (14 locally advanced & unresectable; 31 metastatic) were diagnosed preoperatively while 39 (3 unresectable; 36 metastatic) were diagnosed intra-operatively. Clinical and pathological variables of the study group are shown in Table 1.

The median value for CA19–9 was significantly higher for patients with metastatic disease as compared to unresectable or resectable disease (79 vs 53.9 vs 21.35 IU/ml; p < 0.001). The median value for CEA was not statistically higher for patients with metastatic disease as compared to unresectable or resectable disease (5.1 vs 7.85 vs 3.52 ng/ml; p = 0.20). (Table 2) A cut off value of 72 IU/ml for CA19–9 had a sensitivity of 52% and a specificity of 80% with area under ROC curve (AUC) 0.674 in predicting the metastatic disease, whereas a cutoff value of 5 ng/ml for CEA had a sensitivity of 51% and a specificity of 72% with AUC 0.628 for detection of metastatic disease. (Table 3, Fig. 1a and b). Only 14/56 patients (25%) with Ca 19.9 levels > 72 ng/ml whereas 14/45 patients (37%) with CEA levels > 5 ng/ml were resectable.

Out of 176 patients, 92 patients had resectable disease and underwent curative resection. Except one patient, all had R0 resection. One patient developed surgical complication in the postoperative period and died during the hospital stay and was excluded for the survival analysis. Five patients were lost to follow up. Among remaining 86 patients, forty six patients received chemotherapy while 40 patients did not receive chemotherapy. The median survival of patients who received chemotherapy was similar to those who did not receive chemotherapy group (30 months (95% CI:24–72) vs 29 months (95% CI: 24–75) p value = 0.669). The chemotherapy did not show significant difference in survival in the resectable group. Factors affecting the overall survival in the resectable group of patients (n = 86) were analysed. Median survival of patients with CEA ≤ 4 was significantly higher than CEA > 4 (49 vs 26 months, p value 0.041) and Median survival of patients with CA19–9 ≤ 72 was significantly higher than CA19–9 > 72 (49 vs 24 months, p value 0.019). (Table 4, Fig. 2a and b) Similarly, female patients (p = 0.045), patients with stage T1/T2 (p = 0.001), node negative patients (p = 0.001) and no perineural invasion (p = 0.010) showed significantly better survival. Patients with lymphovascular invasion (present/absent) showed similar survival. However on multivariate analysis, none of the factors was found to be statistically significant in affecting overall survival. (Table 5).

Among the resected patients (n = 86), on follow-up, recurrence was noted in 38 patients (44%). Among these

Table 1 Shows clinicopathological characteristics of GBC patients

| Variables                        | n = 176          |
|----------------------------------|------------------|
| Age in years median (Range)      | 55 (17–80)       |
| Gender, n (%)                    |                  |
| Male: 38 (21.6%)                 |                  |
| Female: 138 (78.4%)              |                  |
| Serum CEA, ng/ml median (Range)  | 4.2 (0.5–304.2)  |
| Serum CA19–9, IU/ml median (Range)| 28.2 (0.6–36,889) |
| Disease status, n (%)            |                  |
| Resectable: 92 (52.3%)           |                  |
| Unresectable: 17 (9.6%)          |                  |
| Metastatic: 67 (38%)             |                  |
| AJCC staging, n (%)              |                  |
| Stage 1: 16 (9.1%)               |                  |
| Stage 2: 25 (14.2%)              |                  |
| Stage 3: 43 (24.4%)              |                  |
| Stage 4A: 17 (9.7%)              |                  |
| Stage 4B: 75 (42.6%)             |                  |

| Variables                        | Group1 (Resectable) | Group2 (Unresectable) | Group3 (Metastatic) | P value   |
|----------------------------------|---------------------|-----------------------|---------------------|-----------|
| Ca19.9 median IU/ml              | 21.35               | 53.9                  | 79                  | < 0.001   |
| CEA median IU/ml                 | 3.5                 | 7.8                   | 5.1                 | 0.201     |

| Variables                        | Group1 (Resectable) | Group2 (Unresectable) | Group3 (Metastatic) | P value   |
|----------------------------------|---------------------|-----------------------|---------------------|-----------|
| Ca19.9 median IU/ml              | 21.35               | 53.9                  | 79                  | < 0.001   |
| CEA median IU/ml                 | 3.5                 | 7.8                   | 5.1                 | 0.201     |
23(60.5%) patients had systemic recurrence alone, 5(13.2%) had local recurrence alone whereas 10(26.3%) patients had both systemic and local recurrence. On univariate analysis of patients having recurrence, CEA > 4 (p value = 0.040), CA19–9 > 37 (p value = 0.013), T stage (T3/ T4, p value 0.001), N stage (N+ p 0.001) and perineural invasion positivity (p 0.012) were found to be statistically significant in predicting recurrence. On multivariate analysis, only CA19–9 > 37 (p value 0.020, hazard ratio 5.803) was found to be statistically significant. (Table 6).

On subgroup analysis of tumour markers in 32 patients who were diagnosed gall bladder cancer incidentally was performed. In metastatic group (n = 9), the median Ca 19.9 and CEA levels were 37.5 ng/ml (IQR: 14.8–299.8); 5.7 IU/ml (IQR: 3.8–40.10) respectively. In unresectable group (n = 1) the Ca 19.9 and CEA levels were 12.56 ng/ml and 6 IU/ml respectively. In resectable group (n = 22), the median Ca 19.9 and CEA levels were 24.7 ng/ml (IQR: 10.1–35.6) and 3 IU/ml (IQR: 2.4–5.0). The Ca 19.9 levels were significantly higher in metastatic group than resectable group (p = 0.039). However CEA levels were not statistically significant in metastatic group compared to resectable group (p = 0.07).

Discussion
GBC is a biologically aggressive disease with poor prognosis and late presentation. Despite screening from the outpatient department 38% patients of GBC without SOJ were found to have metastatic disease at the time of surgery as shown in our previous study [4]. Therefore, it is important to diagnose the advanced nature of the disease preoperatively, to avoid the morbidity related to anesthesia and surgery in these patients.

Predicting metastasis
CA19–9 and CEA are the most commonly used tumor markers in GBC [9, 12]. The role of these markers in predicting metastasis or unresectability needs attention and evaluation. Finding a serum levels of these markers will help to increase the accuracy of predicting the prognosis of these patients. In a study by Wang et al., value of CA19–9 (but not CEA) increased gradually with progression of clinical stages [9]. The current study demonstrated that CA19–9 value increases as the tumor burden increases (p < 0.001) but the same was not true for CEA levels (p = 0.20). Thus, CA19–9 may be useful in predicting the tumor burden in these patients. In our study the cutoff value of CA19–9 > 72 and CEA > 5 had high specificity but low sensitivity in detection of metastatic disease with a AUROC of 0.67 and 0.62 for CA19–9 and CEA respectively. Liu et al. [13] found cut-off levels CA19–9 of 98.9 IU/ml, an independent predictor of resectability in GBC patients who underwent attempted resection with a sensitivity of 76.3% and specificity of 70.8%. They showed CA19–9 levels may predict R0 resection. Shukla PJ et al. [14] in their analysis of 335 patients, which also included 80 patients with

| Table 3 Cutoff value with sensitivity and specificity of tumor markers for detection of metastasis |
| Tumor marker | Cut off value | Sensitivity | Specificity |
|---------------|--------------|-------------|------------|
| CA19–9        | 72 IU/ml     | 52%         | 80%        |
| CEA           | 5 ng/ml      | 51%         | 72%        |

Fig. 1a: ROC curve for CA19–9 for detection of metastasis (Area under curve: 0.674 with a cut-off value of 72 IU/ml). Fig. 1b: ROC curve for CEA for detection of metastasis (Area under curve: 0.628 with a cut-off value of 5 ng/ml)
jaundice, found that when CA19–9 levels exceeded 90 IU/ml, 95% patients had unresectable disease. However, they did not calculate the cut-off levels in their study. Although high levels of CA19–9 ( > 70–100 IU/ml) have been associated with a high probability of unresectable disease, but one should not deny these patients a chance of surgical resection based on the level of tumor markers alone as surgery is the mainstay for curative treatment in these patients. Literature says PET-CT changes the surgical management in 17–23% of patients with GBC (Petrowsky et al. 2006, Corvera 2008 et al) [15, 16]. Therefore we suggest the use of PET-CT in work up algorithm of patients when the CA19–9 is > 72 and CEA > 5 to detect occult metastasis preoperatively, potentially avoiding surgical exploration, particularly when routine imaging does not show any sign of unresectability.

### Prognostic marker

Wen et al. [11] used a time dependent ROC curve and AUROC for prognostic accuracy of the tumor markers. They found AUROC at 5 years for CA19–9 was 0.77, CEA was 0.76 and for combined markers was 0.79 and concluded that the combination of an elevated CEA and CA19–9 was an independent predictor of poor prognosis in GBC patients undergoing resection. We found a statistically significant difference in the survival of patients with CA19–9 > 37 vs ≤37 IU/ml and CEA > 4 vs ≤4 ng/ml in univariate analysis along with other tumour characteristics. However both these factors were not significant in determining overall survival on multivariate analysis. The overall 5-year survival of patients with CEA ≤4 and > 4 was 42.8 and 12.5% respectively. Similarly, patients with CA19–9 ≤37 had a 5-year survival of 40%, whereas none of the patients with CA19–9 > 37 survived for more than 5 years despite curative surgical resection. These observations suggest that preoperative CA19–9 and CEA levels have a utility in prognostication of patients undergoing curative surgical resection. Agarwal et al. [17] noted a 4-year survival of 78% in GBC patients undergoing extended cholecystectomy (n = 33), when CA19–9 levels were less than 20 IU/ml vs 33% when CA19–9 levels were more than 20 IU/ml. They noted that median survival was not reached when CA19–9 levels were less than 20 IU/ml vs 12 months when CA19–9 levels were more than 20 IU/ml [17].

### Predicting recurrence

The elevated preoperative level of CA19–9 has been associated with a high risk of recurrence after curative resection of biliary tract carcinoma in a few published studies including the current study. However, the optimal cut off value of CA19–9 remains controversial. Chung et al. found an optimal cutoff value of preoperative CA19–9 to be 55 IU/ml to predict recurrence in their study [18]. However, Chung et al. included a mix population of all biliary tract cancers in their study (only 20% of patients had GBC) and approximately 40% of patients among them had jaundice. Liu et al. [8] reported a mean value of > 250 IU/ml as cut-off for CA19–9 in predicting recurrence. The higher value reported by Liu et al. could be because they calculated the mean value and not used the ROC curve, or could also be attributed to the differences in study population. Chung et al. [18] found that the recurrence occurred in 61% patients with

| Table 4 Factors affecting overall survival in patients undergoing curative resection (n = 86) |
|---------------------------------------------------------------|
| Variables          | n   | Median survival (months) | 3 yr survival | 5 yr survival | P value (Log rank) |
| Age               |     |                        |              |              |                   |
| ≤50               | 40  | 50                     | 62.2%        | 46.6%        | 0.051             |
| > 50              | 46  | 28                     | 46.3%        | 22.5%        |                   |
| Sex               |     |                        |              |              | 0.045             |
| Female            | 67  | 50                     | 61.5%        | 56.4%        |                   |
| Male              | 19  | 26                     | 34.3%        | 11.4%        |                   |
| CEA               |     |                        |              |              | 0.041             |
| ≤4                | 35  | 49                     | 64.1%        | 42.8%        |                   |
| > 4               | 33  | 26                     | 41.8%        | 12.5%        |                   |
| CA19–9            |     |                        |              |              | 0.019             |
| ≤37               | 59  | 49                     | 66.6%        | 40.0%        |                   |
| > 37              | 27  | 24                     | 29.6%        | –            |                   |
| T stage 1/2       |     |                        |              |              | 0.001             |
| 52                | 50  |                        | 74.5%        | 49.7%        |                   |
| T stage 3/4       | 34  | 16                     | 18.0%        | 0.9%         |                   |
| Node negative     |     |                        |              |              | 0.001             |
| 47                | 55  |                        | 22.3%        | 0.8%         |                   |
| Node positive     | 39  | 24                     | 77.4%        | 57.5%        |                   |
| LVI               |     |                        |              |              | 0.633             |
| No                | 43  | 28                     | 50.0%        | 37.5%        |                   |
| Yes               | 17  | 26                     | 30.3%        | 30.3%        |                   |
| PNI               |     |                        |              |              | 0.010             |
| No                | 42  | 39                     | 57.7%        | 43.3%        |                   |
| Yes               | 18  | 16                     | 15.7%        | 15.7%        |                   |
CA19–9 > 55 compared to 25% when CA19–9 was < 55 IU/ml. In our study, recurrence occurred in 63% patients with CA19–9 > 37 compared to 35% in patients with CA19–9 < 37 reaffirming that high CA 19–9 has significantly higher recurrence after curative surgery. The high preoperative CA19–9 level could also be considered as a criterion for considering patient for adjuvant chemotherapy after curative surgical resection.

In our present study we found CEA > 4, CA19–9 > 37, presence of T3/T4 tumors, node positive disease and presence of perineural invasion were predictors of recurrence. But on multivariate analysis, only CA19–9 > 37 was found to be statistically significant in predicting recurrence after surgery.

CA19–9 was found to be a better tumor marker than CEA in our study, as its median value increases with tumor burden. It has a higher area under ROC for prediction of metastatic disease and is a significant factor in predicting recurrence. Recent studies done to understand the molecular mechanisms of GBC show that the eukaryotic initiation factors (eIFs) monitor protein translational processes via PI3K/AKT/mTOR pathway play a pivotal role in cell growth, proliferation, apoptosis and malignant transformation. Overexpression of eIF6s and
Insulin growth factor-2 mRNA binding protein, (IMP2) have been significantly correlated with advanced tumor and shorter survival of gallbladder cancer patients. Thus, besides the tumor marker CEA and CA 19–9, eIF6 and IMP2 may be used as a prognostic biomarker for overall survival in GBC patients and might be used as a potential therapeutic approach in future [19, 20].

Chronic inflammation is a risk factor for gall bladder carcinoma. IL-6, a pleiotrophic cytokine is involved in such inflammation and if chronically stimulated will have detrimental effects. However, the IL-6 R alpha (interleukin-6 receptor alpha) expression in GBc patients has a good prognosis [21].

The strength of this study are that we included a complete spectrum (both resectable and unresectable) of GBC patients to derive at the significance level of the tumour marker. We excluded patients of GBC with SOJ.

**Table 5** Univariate and multivariate analysis of factors affecting overall survival in patients undergoing curative resection

| Variables     | n     | Univariate | Multivariate |
|---------------|-------|------------|--------------|
| Age < 50      | 40    | 0.058      | 0.520 (0.264–1.022) |
| Age > 50      | 46    |            |              |
| Sex female    | 67    | 0.052      | 0.511 (0.260–1.006) |
| Sex Male      | 19    |            |              |
| CEA < 4       | 35    | 0.049      | 0.473 (0.225–0.996) |
| CEA > 4       | 33    |            |              |
| Ca19.9 < 37   | 59    | 0.024      | 0.463 (0.237–0.903) |
| Ca19.9 > 37   | 27    |            |              |
| T stage 1/2   | 53    | 0.001      | 0.184 (0.093–0.365) |
| T stage 3/4   | 33    |            | 0.368 0.598 (0.195–1.831) |
| Node Negative | 47    | 0.001      | 0.264 (0.132–0.524) |
| Node Positive | 39    |            | 0.692 0.781 (0.229–2.659) |
| LVI No        | 43    | 0.639      | 1.211 (0.544–2.698) |
| LVI Yes       | 17    |            |              |
| PNI No        | 42    | 0.014      | 2.567 (1.212–5.440) |
| PNI Yes       | 18    |            | 1.147 (0.343–3.830) |

**Table 6** Univariate and multivariate analysis for factors affecting recurrence

| Variables     | Recurrence(n) | Univariate | Multivariate |
|---------------|---------------|------------|--------------|
| Age < 50      | 13            | 0.054      | 0.420 (0.174–1.016) |
| Age > 50      | 25            |            |              |
| Sex female    | 26            | 0.072      | 0.379 (0.132–1.089) |
| Sex Male      | 12            |            |              |
| CEA < 4       | 11            | 0.040      | 0.352 (0.130–0.954) |
| CEA > 4       | 19            |            |              |
| Ca19.9 < 37   | 21            | 0.013      | 0.293 (0.111–0.770) |
| Ca19.9 > 37   | 17            |            | 0.020 5.803 (1.324–25.440) |
| T stage 1/2   | 13            | 0.001      | 10.989 (3.861–31.275) |
| T stage 3/4   | 25            |            | 0.412 2.111 (0.354–12.582) |
| Node Negative | 12            | 0.001      | 5.667 (2.222–14.451) |
| Node Positive | 26            |            | 0.484 1.874 (0.322–10.904) |
| LVI No        | 9             | 0.541      | 0.704 (0.228–2.171) |
| LVI Yes       | 19            |            |              |
| PNI No        | 13            | 0.012      | 0.214 (0.064–0.716) |
| PNI Yes       | 15            |            | 0.804 0.788 (0.120–5.164) |
as jaundice by itself can erroneously lead to raised CA19–9, confounding the interpretation of data. Our study is limited by its retrospective analysis of data, which is potentially exposed to selection bias. Secondly, Lewis antigen (non secretory group for CA19–9) was not taken in to account and this could have decreased the accuracy of CA19–9 in predicting advanced disease. There was a limited data on postoperative levels of Ca 19.9 and CEA. Hence the difference between preoperative levels and post operative levels could not be calculated.

**Conclusions**

Rased CA19–9 and CEA predict metastatic disease in patients with GBC without jaundice with a good specificity and may help in prognostication of the patient. CA19–9 is overall better than CEA in predicting tumor burden and recurrence. Patients with raised CA 19–9 levels may be considered for preoperative PET before exploration and for adjuvant chemotherapy after resection.

**Abbreviations**

CEA: Carcinoma Embryonic Antigen; CA19–9: Carbohydrate Antigen 19–9; GBC: Gall Bladder Cancer; SOJ: Surgical Obstructive Jaundice; PET: Positron Emission Tomography; ROC: Receiver operating characteristic; AUROC: Area under ROC curve

**Acknowledgements**

Not applicable.

**Authors’ contributions**

A3 collected and analyzed the data and contributed in writing the manuscript. SSS interpreted the data and analysis and had a major contribution in writing and editing of the manuscript. PKM contributed in writing the manuscript. Nimisha contributed in collection and analysis of data. BM performed the biochemical analysis of the samples and contributed in writing the manuscript. HHN and PKM did the proof reading of the manuscript and contributed in writing the manuscript. All authors read and approved the final manuscript.

**Funding**

No grant support or assistance.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Written informed patient consent was obtained for this research. Ethical approval was not required due to the retrospective nature of the study (Retrospective observational study). The Medical Council of India’s Code of Medical Ethics permits waiver of ethics review in a retrospective study if the patient’s identity is not revealed. [Reference: Medical Council of India. Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002. Gazette of India dated 06.04.02, part III, section 4. [cited 2006 March 25] Available from: http://mohfw.nic.in/code.htm].

**Consent for publication**

Written informed patient consent was obtained for this research.

**Competing interests**

The authors declare no conflict of interest.

**Author details**

1Department of Gastrointestinal Surgery, Govind Ballabh Pant Institute of Post Graduate Medical Education and Research, Room no 218, Jawahar Lal Nehru Marg, New Delhi 110002, India. 2Department of Biochemistry, Govind Ballabh Pant Institute of Post Graduate Medical Education and Research, New Delhi, India.

**Received:** 13 October 2019 **Accepted:** 24 August 2020

**Published online:** 31 August 2020

**References**

1. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109.
2. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.
3. Kim SJ, Lee JM, Lee JY, et al. Accuracy of preoperative T-staging of gallbladder carcinoma using MDCT. AJR Am J Roentgenol. 2008;190:74–80.
4. Mishra PK, Saluja SS, Prithiviraj N. Estimation of early mortality in patients with gallbladder cancer. J Surg Oncol. 2014;110:548–51.
5. National Comprehensive Cancer Network. Hepatobiliary cancer (version 2. 2017), 2017.
6. Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M, et al. Elevated CA 19-9 portends poor prognosis in patients undergoing resection for biliary malignancies. HPB. 2010;12:134–8.
7. Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, et al. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer. 1990;45:B21–4.
8. Liu F, Hu HJ, Ma WJ, Yang Q, Wang JK, Li FY. Prognostic significance of neutrophil-lymphocyte ratio and carbohydrate antigen 19-9 in patients with gallbladder carcinoma. Medicine (Baltimore). 2019 Feb;98(8):e14550.
9. Wang YF, Feng FL, Zhao XH, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 2014;20:4085–92.
10. Wen Z, et al. Elevation of CA19-9 and CEA is associated with a low prognosis in patients with resectable gallbladder carcinoma; HPB. 2017. p. 1–6.
11. Zhu AX, Pavlik TM, Kooby DA, Scheffer TE, Vauthey J-N. Gallbladder cancer: AJCC Cancer staging manual. 8th ed. New York: Springer International Publishing; 2017. p. 303–9.
12. Yu T, Yu H, Cai X. Preoperative prediction of survival in resectable gallbladder cancer by a combined utilization of CA 19-9 and carcinoembryonic antigen et al. Chin Med J. 2014;127:2299–303.
13. Liu F, Wang JK, Ma WJ, Yang Q, Hu HU, Li FY. Clinical value of preoperativeCA19-9 levels in evaluating resectability of gallbladder carcinoma. ANZ J Surg. 2019 Mar;89(3):E76–80.
14. Shuiki P, Uebe R, Seito T, Nakanishi M, Moriya K, Shikida H, et al. A new scoring system for gallbladder cancer (surgical treatment algorithm): an analysis of 345 patients. Ann Surg Oncol. 2008 Nov;15(11):3132–7.
15. Conera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, Jarnagin WR. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008 Jan;206(1):57–65.
16. Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tschopp S, Ramon J, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006 Jul;45(1):43–50.
17. Agrawal S, Lawrance A, Saxena R, Does CA 19-9 Have Prognostic Relevance in Gallbladder Carcinoma (GBC)? J Gastrointestinal Cancer. 2018 Jun 1;49(2):144–9.
18. Chung MJ, Lee KJ, Bang S, Park SW, Kim KS, Lee WJ, Song SY, Chung JB, Park JY. Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer. Ann Surg Oncol. 2011 Jun;18(6):1651–6.
19. Golob-Schwarz N, Wodlej C, Kleinegger F, et al. Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer. J Cancer Res Clin Oncol. 2019;145:2699–711.
20. Kessler SM, Lederer E, Lagali S, et al. IMP2/GTF2B/P2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer. Oncotarget. 2017;8(52):9736–45.
21. Kleinegger F, Hofer E, Wodlej C, et al. Pharmacologic IL-6Ra inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Biochim Biophys Acta Mol basis Dis. 2019;1865(2):308–21.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.